Mayne Pharma
John Clark has diverse work experience in various companies. John started their career at GSK where they held multiple roles such as Business Process Improvement Specialist, Senior District Sales Manager, and Manager - Sales Training. In these roles, they were involved in implementing Lean Six Sigma principles and processes, leading sales teams, and designing and facilitating training programs. John also worked at Mayne Pharma as a Director - Marketing, Women's Health, and Associate Director - Sales Force Solutions. Additionally, they worked as a Freelance Clinical Investigator Event Producer at IQVIA. Before that, they were the President of WoodBuckle, Inc. Overall, John Clark has a strong background in marketing, sales, and process improvement.
John Clark earned a Bachelor of Business Administration (B.B.A.) in International Business from The University of Georgia in 1989. John later pursued a Master of Business Administration (M.B.A.) in Business Management from the University of Notre Dame - Mendoza College of Business, completing their degree between 2007 and 2009. In 2008, they also obtained an Executive Education certification in International Business/Trade/Commerce from the University of Oxford. Additionally, they obtained a Lean Six Sigma Black Belt certification from Villanova University in 2015.
This person is not in any offices
Mayne Pharma
1 followers
Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing branded and generic pharmaceuticals. It operates through four segments: Generic Products (GPD), Specialty Brands (SBD), Metrics Contract Services (MCS) and Mayne Pharma International (MPI). The GPD segment is engaged in the manufacture and distribution of generic pharmaceutical products in the United States. The SBD segment markets and distributes specialty branded pharmaceutical products in the United States. The MCS segment is engaged in the provision of contract analytical and pharmaceutical development services to third-party customers in the United States. The MPI segment is engaged in Australian manufacture and sale of branded and generic pharmaceutical product globally and provision of contract manufacturing services to third-party customers within Australia.